Brentuximab as a Treatment for CD30+Mycosis Fungoides and Sézary Syndrome

JAMA Dermatology - United States
doi 10.1001/jamadermatol.2014.1629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Regulatory T Cells and Immunodeficiency in Mycosis Fungoides and Sézary Syndrome

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Treatment of Patient With Advanced Folliculotropic Mycosis Fungoides/Sézary Syndrome With Lenalidomide

The Internet Journal of Dermatology
2009English

Oral Mycosis Fungoides With CD30+ Large Cell Transformation Successfully Treated With Brentuximab Vedotin

JAAD Case Reports
Dermatology
2019English

Aggressive Mycosis Fungoides/Sézary Syndrome in Nigeria: Case Report and Literature Review

International Journal of Research in Dermatology
2019English

Long-Term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome

Archives of Dermatology
2003English

Mycosis Fungoides and Sézary Syndrome: 2019 Update on Diagnosis, Risk‐stratification, and Management

American Journal of Hematology
Hematology
2019English

Expression of Thymidine Phosphorylase in Lymph Nodes Involved With Mycosis Fungoides and Sézary Syndrome

Advances in Hematology
Hematology
2011English

Concurrent B-Cell Follicular and Refractory CD30+ Large Cell Transformation of Mycosis Fungoides Responsive to Rituximab and Brentuximab Vedotin

Journal of Blood Disorders & Transfusion
2015English

CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides

American Journal of Surgical Pathology
AnatomyForensic MedicinePathologySurgery
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy